Parametrica Management Ltd cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 31.4% during the fourth quarter, HoldingsChannel reports. The fund owned 9,500 shares of the biopharmaceutical company’s stock after selling 4,339 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 4.6% of Parametrica Management Ltd’s holdings, making the stock its 8th biggest […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CEO Yvonne Greenstreet sold 7,615 shares of the stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $1,481,802.85. Following the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued […]
Sumitomo Mitsui Financial Group began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued a neutral rating and a $220.00 price objective on the biopharmaceutical company’s stock. Several other brokerages have also recently issued reports on ALNY. Morgan Stanley raised […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) President Akshay Vaishnaw sold 2,392 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total transaction of $465,459.28. Following the transaction, the president now directly owns 17,890 shares in the company, […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) CFO Jeffrey V. Poulton sold 977 shares of the business’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $190,114.43. Following the completion of the transaction, the chief financial officer now owns 11,706 shares […]